Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients

Schulze, Maren; Boehle, Arnd S; Kurdow, Roland; Dohrmann, P.; Henne‐Bruns, Doris

doi:10.1016/s0003-4975(01)02586-3

Cited by 92 publications

(64 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TTP combined with closed drainage and simple negative pressure suction is an effective therapy for malignant and refractory benign pleural effusions (55)(56)(57). In our study, TTP was applied through VATS and then closed thoracic drainage combined with simple negative pressure suction was administered to each patient.…”

Section: Discussionmentioning

confidence: 92%

EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy

Guo

Wan²,

Tian³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. The aim of the present study was to evaluate the therapeutic effects and adverse reactions of Tarceva treatment for malignant pleural effusion (MPE) caused by metastatic lung adenocarcinomas. One hundred and twenty-eight patients who failed first-line chemotherapy drug treatment were divided into a mutation and a non-mutation group according to the presence or absence of epidermal growth factor receptor (EGFR) mutations. Each patient received closed drainage combined with simple negative pressure suction after thoracoscopic talc poudrage pleurodesis and oral Tarceva treatment. Short-term and long-term clinical therapeutic effects of Tarceva were evaluated. The EGFR mutation rate in pleural metastatic tissues of lung adenocarcinoma acquired through video-assisted thoracoscopic surgery was higher compared to that in surgical resection specimens, plasma specimens and pleural effusion specimens compared to previously reported results. There were significant statistical differences in the average extubation time (p<0.01), drainage volume of pleural effusion (p<0.05), Karnofsky score and formation of encapsulated pleural effusion 4 weeks after surgery (p<0.05) between these two groups. The number of patients with mild pleural hypertrophy in the mutation group was significantly higher compared to the non-mutation group (p<0.01), while the number of patients with severe pleural hypertrophy was significantly reduced (p<0.05). There was significant statistical discrepancy between these two groups in terms of improvement of peripheral blood carcinoembryonic antigen and tissue polypeptide antigen after 4 weeks of therapy. The complete remission rate and the efficacy rate were higher in the mutation group compared to that in the non-mutation group (p<0.05). There was a longer overall survival time after Tarceva treatment in patients with EGFR mutations than those without EGFR mutation. EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy. Detection of EGFR mutations may determine the responsiveness of malignant pleural effusion to Tarceva treatment.

show abstract

Section: Discussionmentioning

confidence: 92%

EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy

Guo

Wan²,

Tian³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Furthermore, treatment options for patients with MPE are often limited by their poor functional status associated with advanced malignancy. Palliative surgical decortication is not recommended for this patient population because it requires prolonged hospitalization, and morbidity and mortality are high [45,46]. Indwelling pleural catheters have been shown to provide symptom relief for 48-94 % of patients with MPE with trapped lung [47][48][49].…”

Section: Nonexpanding Lungmentioning

confidence: 99%

“…Minimizing procedure-related risks and hospitalization time for these patients is of paramount importance. Pleuroperitoneal shunts have also been used for recurrent drainage of pleural fluid but are limited by high morbidity, shunt failure, translocation of malignant cells into the peritoneal cavity, and lower patient compliance [46]. Intrapleural fibrinolysis with urokinase may improve radiographic lung re-expansion of loculated MPE with trapped lung, but further study of this palliative intervention is required [50].…”

Section: Nonexpanding Lungmentioning

confidence: 99%

Management options for the complicated pleural space

Hsia

Musani

2013

Curr Respir Care Rep

View full text Add to dashboard Cite

Clinicians frequently encounter patients with malignant and benign diseases involving the pleural space.Complications from these disease processes pose clinical challenges that often require a multi-disciplinary management approach. Here we discuss therapeutic options available for complicated diseases of the pleural space, including loculated malignant effusions, complicated pleural infections, hemothorax, nonexpanding lung, pleural thickening, and persistent bronchopleural fistulas. Our objective is to review current literature on management of these complex issues.

show abstract

“…The evaluation of efficacy was based on the relief of symptoms and absence or reduction of pleural fluid (5,6). Patients with symptomatic improvement and no detectable fluid on the roentgenogram prior to discharge are deemed a success.…”

Section: Case Reportmentioning

confidence: 99%

Inhibition of pleural metastasis of collecting duct carcinoma of the kidney by modified cytokine-induced killer cells: A case report and review of the literature

et al. 2010

View full text Add to dashboard Cite

Abstract. Collecting duct carcinoma (CDC) or Bellini duct carcinoma of the kidney is a rare, but highly aggressive renal epithelial malignancy, with an extremely poor prognosis. Modified cytokine-induced killer (mCIK) cells were injected into the pleural cavity to treat pleural metastasis of CDC. The patient, a 33-year-old male, was admitted to hospital for further treatment for severe pleural metastasis of CDC. We cured the pleural metastasis through intrapleural infusion with mCIK cells. After receiving this innovative treatment, the patient exhibited a positive response: the cough, dyspnea, chest distress and thoracalgia were evidently relieved, while the pleural fluid became clear after exhibiting haematodes and its level decreased significantly. The patient achieved partial success. This novel immunotherapy method is a promising treatment for patients with refractory pleural metastasis. IntroductionCollecting duct carcinoma (CDC) or Bellini duct carcinoma, which accounts for 1-3% of all renal neoplasms (1), is a rare variant of renal cell carcinoma (RCC) originating in the collecting duct epithelium and occurring more frequently in relatively young adults (2). Patients with CDC often require a more aggressive clinical course, have a poor long-term survival rate and, currently no standard treatment regimens exist (3). CDC and clear cell RCC typically present with a renal mass, macroscopic hematuria and associated flank pain. However, the majority of patients with CDC show evidence of metastatic disease at the time of presentation (3). Pleural metastasis of CDC is resistant to chemotherapy and radiotherapy, while immunotherapy, especially adoptive immune cell treatment, becomes a promising treatment for pleural metastasis. The present study evaluated a patient with pleural metastasis of CDC who achieved partial success following intrapleural infusion with modified cytokine-induced killer (mCIK) cells. Case reportA 33-year-old male with no significant past medical history was referred for urology review after a mass was found during a regular examination. A left radical nephrectomy was performed in December 2006 in the First Affiliated Hospital, Kunming Medical College, China. The pathology revealed CDC (Fig. 1) in the left kidney with no lymph node metastasis. After 1 year, the patient suffered from constant coughing, dyspnea, chest distress and thoracalgia. A chest X-Ray revealed a left pleural effusion. The pleural effusion recurred 1 month after B-ultrasound-guided therapeutic thoracentesis. For further treatment, the patient was referred to our institution on May 5th, 2008.A physical examination revealed a dull sound on percussion and the breath sounds disappeared below the sixth left rib. A computed tomography (CT) scan of the chest, abdomen and pelvis revealed no local recurrence and no lymph node metastasis, although severe pleural metastasis was noted. The examination results revealed that the left pleural had thickened, the pleural effusion was partly encapsulated and there was left pulmonary atelect...

show abstract

Effective treatment of malignant pleural effusion by minimal invasive thoracic surgery: thoracoscopic talc pleurodesis and pleuroperitoneal shunts in 101 patients

Cited by 92 publications

References 13 publications

EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy

EGFR mutations predict a favorable outcome for malignant pleural effusion of lung adenocarcinoma with Tarceva therapy

Management options for the complicated pleural space

Inhibition of pleural metastasis of collecting duct carcinoma of the kidney by modified cytokine-induced killer cells: A case report and review of the literature

Contact Info

Product

Resources

About